Last reviewed · How we verify
Inactivated Poliomyelitis vaccine
Inactivated poliomyelitis vaccine stimulates the immune system to produce antibodies against all three serotypes of poliovirus, providing protection against polio infection.
Inactivated poliomyelitis vaccine stimulates the immune system to produce antibodies against all three serotypes of poliovirus, providing protection against polio infection. Used for Poliomyelitis prevention in infants, children, and adults.
At a glance
| Generic name | Inactivated Poliomyelitis vaccine |
|---|---|
| Also known as | IMOVAX Polio™ (IPV), IMOVAX Polio ™ (IPV), IMOVAX Polio |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains chemically inactivated (killed) poliovirus particles that cannot cause disease but are immunogenic. When administered, these inactivated viruses trigger both humoral (antibody) and cellular immune responses, leading to the production of neutralizing antibodies against poliovirus types 1, 2, and 3. This immune memory protects vaccinated individuals from infection if exposed to wild-type poliovirus.
Approved indications
- Poliomyelitis prevention in infants, children, and adults
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Myalgia
Key clinical trials
- Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine (PHASE4)
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations (PHASE4)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children (PHASE2)
- Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inactivated Poliomyelitis vaccine CI brief — competitive landscape report
- Inactivated Poliomyelitis vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI